EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world Treatment Patterns of Novel Drugs in Relapsed or Refractory Acute Lymphoblastic Leukemia Patients in Japan

Toyoki Moribe iD, Linghua Xu iD, Kentaro Tajima iD, Naohiro Yonemoto iD

Future Oncology · 01.06.2023 · 19 (19) · 1343-1356

DOI: 10.2217/fon-2022-1314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, online erschienen am 22.05.2023. Verfasst von Toyoki Moribe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Medical Affairs, Pfizer Japan Inc. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Japan Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate treatment patterns of novel therapies (inotuzumab ozogamicin (inotuzumab), blinatumomab, and tisagenlecleucel) in patients with acute lymphoblastic leukemia (ALL) in a Japanese real-world setting. Patients & Methods: Patients with ALL diagnoses from a Japanese claims database were examined.

Results

We included 194 patients (97 patients were prescribed inotuzumab; 97 patients were prescribed blinatumomab; and no patient was prescribed tisagenlecleucel); 81.4% in the inotuzumab group and 78.4% in the blinatumomab group were prescribed chemotherapy prior to the initiation of those drugs. Most patients were prescribed subsequent treatment (60.8 and 58.8%, respectively). A small number of patients were prescribed sequential treatment of inotuzumab-to-blinatumomab or blinatumomab-to-inotuzumab (20.3 and 10.5%, respectively).

Conclusion

This study revealed inotuzumab and blinatumomab treatment features in Japan. In acute lymphoblastic leukemia (ALL), the increase in leukemic cells prevents the production of normal blood cells. As a result, people with ALL become more susceptible to anemia, fatigue, infections, fever, bruising and bleeding easily. ALL progresses rapidly without treatment. In recent years, new therapeutic drugs, including inotuzumab and blinatumomab, have become available; however, it remains unclear how they have been used in clinical practice. In this report, we assess how they are used in clinical practice using a large database to collect the clinical data of ALL patients. To see the treatment pattern, we found that most of the patients (81.4% of patients who received inotuzumab and 78.4% of those who received blinatumomab) had received chemotherapy before starting treatment with inotuzumab or blinatumomab. After patients ended treatment with inotuzumab or blinatumomab, 60.8% of patients who received inotuzumab and 58.8% of those who received blinatumomab received the next therapies, including chemotherapy. However, a small number of patients had received inotuzumab-to-blinatumomab or blinatumomab-to-inotuzumab (20.3 and 10.5%, respectively). These findings show the real-world treatment patterns of inotuzumab and blinatumomab; that is, both inotuzumab and blinatumomab are more likely to be prescribed to patients who might not have enough efficacy from prior chemotherapy or might have had to stop chemotherapy early due to side effects. Overall, there is clinical meaningful information from our findings of how inotuzumab and blinatumomab have been used for treatment of ALL and this information could improve the clinical practice of ALL in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificHumansJapanInotuzumab OzogamicinRemission Induction

Stichwörter der Autor:innen

Japanese claims dataacute lymphoblastic leukemiablinatumomabdatabase studyinotuzumabminimal residual diseaseprescription patternreal-worldrelapsed or refractorysubsequent therapy

Substanzen

Inotuzumab OzogamicinAntibodies, Bispecific

Autor:innen und Institutionen

  • Oncology Medical Affairs, Pfizer Japan Inc.
  • Health & Value, Pfizer Japan Inc.

ORCID-Profile: Toyoki Moribe, Linghua Xu, Kentaro Tajima, Naohiro Yonemoto

Förderung

  • Pfizer Japan Inc.

Zitieren

APA

Moribe, T., Xu, L., Tajima, K., & Yonemoto, N. (2023). Real-world Treatment Patterns of Novel Drugs in Relapsed or Refractory Acute Lymphoblastic Leukemia Patients in Japan. Future Oncology, 19(19), 1343-1356. https://doi.org/10.2217/fon-2022-1314

Vancouver

Moribe T, Xu L, Tajima K, Yonemoto N. Real-world Treatment Patterns of Novel Drugs in Relapsed or Refractory Acute Lymphoblastic Leukemia Patients in Japan. Future Oncology. 2023;19(19):1343-1356. doi:10.2217/fon-2022-1314

BibTeX
@article{Moribe2023,
  author = {Moribe, Toyoki and Xu, Linghua and Tajima, Kentaro and Yonemoto, Naohiro},
  title = {Real-world Treatment Patterns of Novel Drugs in Relapsed or Refractory Acute Lymphoblastic Leukemia Patients in Japan},
  journal = {Future Oncology},
  year = {2023},
  volume = {19},
  number = {19},
  pages = {1343--1356},
  doi = {10.2217/fon-2022-1314}
}
Kostenlos starten →